Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Insulin Delivery May 19 | 2023FDA Clears Beta Bionics iLet ACE Pump and iLet Dosing Decision SoftwarePurchase Blast
$599
Posted in: SGLT2i May 18 | 2023US Supreme Court Rules in Favor of Regeneron/Sanofi Praluent LitigationPurchase Blast
$599
Posted in: Other May 17 | 2023Intercept Faces Uphill Battle for Impending FDA Adcom; Briefing Documents ReleasedPurchase Blast
$599
Posted in: Other May 16 | 2023Viking Topline Ph2b VK2809 NASH Data; Chinook and Ionis Partner to Develop ASO Therapy for CKDPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, SGLT2i May 12 | 2023Structure Therapeutics Advances Oral GLP-1RA to Ph2; Embecta and Tidepool Partner for T2DM Patch Pump AID Development; New SOLOIST-WHF AnalysisPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other May 11 | 2023Senate Targets PBMs and Insulin Manufacturers; Zealand and Dario Q1 ’23 Earnings; Cytokinetics Initiates Ph1 Trial for Potential HFpEF TherapyPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Insulin Delivery, Other May 10 | 2023BI and Zealand Announce Positive Ph2 BI 456906 Obesity Results; Senseonics and MannKind Q1 ’23 Earnings; Sanofi Study Demonstrates Benefit of Dario; MyFitnessPal and Google Health CGM Integration; Diamyd’s Remygen Fails To Support Durable Treatment EffectPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring, Other, SGLT2i May 09 | 2023AZ’s Farxiga Receives FDA Approval for DELIVER; Esperion, Xeris, Madrigal, and Sigilon Q1 ’23 Earnings; Ascensia Expands Eversense PASS Program; and Glooko Redesigns AppPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other May 08 | 2023Akebia and Viatris Q1 ’23 EarningsPurchase Blast
$599
Posted in: Insulin Delivery, Other May 05 | 2023Insulet Q1 ’23 Earnings and Organizational Changes; Tidepool Secures Funding to Support Tidepool Loop for AndroidPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Insulin Delivery, Other May 04 | 2023Novo Nordisk, Tandem, Alnylam, and Regeneron Q1 ’23 EarningsPurchase Blast
$599
Posted in: Other, SGLT2i May 03 | 2023Ionis, Lexicon, and Amarin Q1 ’23 Earnings; AstraZeneca Collaborates with Sernova for Cell TherapiesPurchase Blast
$599
Posted in: GLP-1RA, Other May 02 | 2023D&D Pharmatech Announces Positive Ph1 DD01 NAFLD Topline Results; FDA Clears NeuroBo’s IND for Ph2a DA-1241 NASH Trial; Pfizer Q1 ’23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Other May 01 | 2023Vertex Q1 ’23 Earnings; Lannett Restructures Debt and Files for BankruptcyPurchase Blast
$599
Posted in: Glucose Monitoring, Other Apr 28 | 2023Dexcom, Amgen, and Merck Q1 ’23 Earnings; JDRF and Humacyte Collaborate on Insulin-Producing Biovascular Pancreas for T1DMPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Apr 27 | 2023Intercept, AZ, and Sanofi Q1 ’23 Earnings; Sanofi Completes Provention Acquisition; DRI Sells Tzield Royalties to SanofiPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other Apr 27 | 2023Lilly to Use PRV for Tirzepatide Obesity Submission Following Positive SURMOUNT-2 Topline Results; Lilly, Viking, and Teladoc Q1 ’23 EarningsPurchase Blast
$599
Posted in: Insulin Delivery, Other Apr 26 | 2023Medtronic Resolves FDA Warning Letter; HSR Waiting Period for Sanofi’s Provention Bio Acquisition Expires; Roche Q1 ’23 EarningsPurchase Blast